Peer AI, a leading agentic AI platform for life sciences regulatory documentation, today announced $12.1 million in total funding, led by Flare Capital Partners and SignalFire. Other investors included Greycroft, Atria, Alumni Ventures, Gaingels, and Mana Ventures, along with strategic angel investors from across the life sciences, healthcare, and technology industries.
Generating documentation for regulatory approval remains a critical drug development bottleneck. New drugs require over 200,000 pages spanning more than 1,500 unique documents. Manual and fragmented processes lead to missing data and discrepancies, often stalling approvals. Nearly one-third of FDA submissions have quality issues, and regulators reject almost 75% of applications, causing delays of 435 days.
Read More – Bain Capital Closes Fourteenth Flagship Private Equity Fund, at $14 Billion
The Peer AI platform deploys purpose-built, domain-specific AI agents combined with an intuitive AI-powered user interface that allows medical writers to apply their subject matter expertise at critical control points during documentation workflows. Top 20 pharmas and emerging biotechs are saving thousands of hours and improving quality of regulatory documents across pre-clinical, clinical, regulatory affairs, and chemistry, manufacturing, and controls (CMC) with Peer AI.
Customers are accelerating drafting times by 55–94%, cutting costs, and improving consistency and accuracy, while maintaining regulatory compliance. Medical writing teams have reduced clinical study report (CSR) drafting time from 40 to 17 working days and cut protocol turnaround from 6-8 weeks to just one week. Daily active use has grown 3X in the first three quarters of 2025, while overall platform volume has increased 6X, demonstrating strong adoption.
Read More – Tycho AI Raises $10M in Series A Funding
